spleen
tyrosin
kinas
syk
sirna
ige
fceri
piceatannol
b
r
c
spleen
tyrosin
kinas
syk
bind
itambear
receptor
wide
varieti
cell
type
one
exampl
activ
mast
cell
basophil
eosinophil
via
stimul
fceri
receptor
igeallergen
complex
possibl
role
syk
inflammatori
signal
cascad
led
develop
pharmacolog
agent
design
block
syk
catalyt
domain
potenti
novel
therapeut
whilst
enzymat
activ
syk
lend
toward
design
smallmolecul
inhibitor
attent
focus
possibl
target
syk
express
use
antisens
oligonucleotid
altern
mean
antiinflammatori
therapi
studi
compar
abil
multipl
optim
syk
sirna
sequenc
smallmolecul
syk
inhibitor
block
fcerimedi
signal
transduct
degranul
tnfa
secret
basophil
cell
line
also
character
specif
sirna
sequenc
regard
offtarget
induct
interferoninduc
gene
identifi
singl
sirna
sequenc
display
favor
profil
effici
syk
knockdown
blockag
fcerimedi
signal
transduct
degranul
tnfa
secret
lack
induct
effect
sirna
compar
syk
kinas
domain
inhibitor
identif
activ
specif
syk
sirna
could
basi
develop
therapeut
syk
sirna
inflammatori
diseas
spleen
tyrosin
kinas
syk
express
wide
immun
system
includ
leukocyt
platelet
dendrit
cell
wide
varieti
cell
surfac
receptor
immun
system
cell
cell
type
postul
transduc
signal
via
bind
activ
syk
part
includ
receptor
bear
immunoreceptor
tyrosinebas
activ
motif
itam
howev
nonitambear
receptor
erythropoietin
lipopolysaccharid
endotoxinlp
also
postul
signal
via
activ
syk
fceri
receptor
complex
express
mast
cell
basophil
eosinophil
signal
transduct
follow
bind
igeallergen
lead
syk
bind
phosphoryl
syk
believ
mediat
direct
phosphoryl
sever
protein
within
inflammatori
complex
includ
linker
activ
cell
lat
leukocyt
vav
follow
assembl
activ
complex
protein
activ
mapk
calciumflux
phosphoryl
lead
degranul
lipid
mediat
cytokin
synthesi
syk
gather
great
deal
attent
potenti
novel
target
treatment
allerg
inflammatori
disord
particular
sever
smallmolecul
inhibitor
syk
kinas
domain
shown
efficaci
human
anim
model
allerg
diseas
recent
advanc
use
small
interf
rna
sirna
technolog
mean
posttranscript
gene
silenc
provid
potenti
altern
use
smallmolecul
inhibitor
inhibit
diseas
target
studi
design
rang
differ
syk
sirna
sequenc
test
abil
knockdown
syk
rat
basophil
cell
line
syk
sirna
also
test
specif
investig
induct
interferon
respons
analyz
express
ifninduc
protein
tetratricopeptid
characterist
inflammatori
respons
viral
dsrna
select
sirna
display
combin
effici
specif
knockdown
syk
compar
previous
publish
syk
kinas
inhibitor
piceatannol
effect
fceri
signal
transduct
basophil
degranul
identif
specif
cellularli
activ
syk
sequenc
studi
provid
basi
develop
syk
sirna
complex
vivo
model
inflammatori
diseas
individu
duplex
sirna
purchas
thermo
fisher
scientif
lafayett
co
appli
biosystemsambion
austin
tx
antibodi
syk
bactin
lat
purchas
santa
cruz
biotechnolog
heidelberg
germani
antibodi
syk
phosphoerk
map
kinas
obtain
cell
signal
technolog
danver
high
affin
ige
receptor
fceri
antibodi
bd
bioscienc
san
jose
ca
phospholat
phosphotyrosin
antibodi
purchas
millipor
billerica
mous
antidnp
ige
antibodi
clone
kind
gift
dr
takeshi
kono
nippon
boehring
ingelheim
co
ltd
tokyo
bovin
serum
dnpbsa
purchas
invitrogen
karlsruh
germani
piceatannol
purchas
merck
darmstadt
germani
cell
atcc
routin
cultur
minimum
essenti
medium
mem
supplement
fetal
calf
serum
fc
treatment
cell
pharmacolog
agent
later
analysi
protein
western
blot
cell
seed
plate
cultur
overnight
cell
wash
phosphat
buffer
salin
pb
incub
min
mem
without
fb
plu
either
inhibitor
vehicl
dimethyl
sulfoxid
dmso
cell
activ
min
addit
antifceri
antibodi
lgml
cell
wash
icecold
pb
lyse
min
lysi
buffer
mm
nacl
mm
tri
ph
mm
edta
mm
naf
lm
na
vo
supplement
halt
proteas
inhibitor
cocktail
halt
phosphatas
inhibitor
cocktail
thermo
fisher
scientif
rockford
il
lysat
clear
centrifug
prepar
western
blot
addit
nupag
sampl
reduc
agent
ld
sampl
buffer
invitrogen
nucleofector
l
kit
lonza
cologn
ag
germani
use
electropor
cell
sirna
cell
electropor
cuvett
nucleofector
l
solut
nm
sirna
use
nucleofector
devic
lonza
program
cell
dilut
well
plate
fc
give
final
sirna
concentr
nm
cell
cultiv
day
prior
applic
cellular
assay
analysi
syk
mrna
level
taqman
pcr
describ
follow
section
dharmafect
sirna
transfect
reagent
thermo
fisher
scientif
use
transfect
mous
embryon
fibroblast
mef
cell
analysi
induct
interferon
ifn
induc
gene
mef
cell
routin
cultur
fc
seed
concentr
plate
grown
overnight
reach
confluenc
cell
transfect
nm
sirna
mix
dharmafect
sirna
transfect
reagent
follow
h
cultur
mrna
analyz
taqman
pcr
quantit
analysi
gene
express
total
rna
isol
cell
cultur
lysat
accord
rneasi
protocol
qiagen
hilden
germani
purifi
total
rna
store
gene
express
level
determin
taqman
analysi
sequenc
detect
system
appli
biosystem
inc
foster
citi
ca
use
taqman
ez
rtpcr
reagent
kit
appli
biosystem
revers
transcript
pcr
amplif
abi
prism
optic
reaction
plate
appli
biosystem
detect
respect
transcript
follow
primer
probe
use
sykrat
appli
biosystem
sykmous
appli
biosystem
rna
poliirat
forward
primer
gcaggcgag
revers
primer
present
express
level
normal
rel
quantiti
transcript
divid
mean
valu
respect
control
group
display
control
valu
cell
lysat
load
onto
nupag
bistri
gel
invitrogen
transfer
immobilonp
transfer
membran
millipor
billerica
wet
blot
block
block
buffer
nonfat
milk
tb
membran
incub
gentl
agit
respect
primari
antibodi
dilut
block
buffer
h
room
temperatur
membran
wash
four
time
min
tbst
tb
tween
incub
peroxidaseconjug
secondari
antibodi
jackson
immunoresearch
europ
ltd
suffolk
uk
dilut
block
buffer
jackson
immunoresearch
europ
ltd
suffolk
uk
membran
wash
tbst
describ
western
blot
develop
use
enhanc
chemiluminesc
ecl
reagent
perkinelm
waltham
accord
manufactur
instruct
membran
case
strip
restor
western
blot
strip
buffer
thermo
fisher
scientif
analyz
addit
antibodi
releas
bhexosaminidas
enzym
activ
cell
use
quantifi
readout
degranul
one
day
follow
transfect
cell
sirna
media
follow
transfect
sirna
cell
incub
describ
mous
antidnp
ige
antibodi
follow
day
cell
wash
cultur
h
fc
plu
dnpbsa
ngml
supernat
clear
centrifug
analyz
level
rat
tnfa
use
rat
tnfa
immunoassay
r
system
minneapoli
mn
histamin
use
specif
enzym
immunoassay
eia
immunotech
czech
republ
accord
manufactur
instruct
ten
sirna
sequenc
aj
design
syk
aim
knock
syk
rat
cell
line
fig
sequenc
base
refseq
inform
human
mous
rat
syk
mrna
sequenc
af
homolog
rat
syk
alon
wherea
sequenc
gj
pan
sirna
complet
homolog
rat
mous
human
syk
transcript
cell
transfect
sirna
describ
section
syk
mrna
level
determin
use
taqman
pcr
fig
syk
level
normal
rna
polymeras
ii
sampl
sirna
gapdh
well
cell
electropor
absenc
sirna
use
neg
control
two
control
led
minor
decreas
syk
mrna
level
compar
untreat
cell
sequenc
potent
sirna
regard
syk
mrna
knockdown
meanwhil
sequenc
least
potent
whole
cell
protein
extract
also
analyz
syk
express
western
blot
specif
antibodi
fig
control
level
bactin
also
examin
ensur
equal
load
cellular
protein
sampl
syk
protein
level
reduc
manner
consist
potenc
sirna
toward
syk
mrna
level
sequenc
display
potent
knockdown
syk
protein
speci
specif
induct
interferon
ifn
express
doubl
strand
rna
dsrna
compris
first
line
cellular
defens
viral
infect
viral
dsrna
activ
rang
cellular
pathway
includ
dsrna
recognit
protein
pkr
tolllik
receptor
oligoadenylatedepend
ribonucleas
l
rnase
l
lead
inhibit
cellular
translat
express
stress
respons
gene
includ
ifn
follow
ifn
signal
wave
gene
express
includ
ifnstimul
gene
isg
function
block
viral
replic
activ
ifn
respons
also
demonstr
sirna
transfect
cell
complic
therapeut
potenti
molecul
particular
syk
consid
major
target
inflammatori
disord
induct
inflammatori
mediat
due
antivir
cellular
respons
would
unaccept
sideeffect
design
syk
sirna
therapeut
express
ifninduc
protein
tetratricopeptid
analyz
mous
embryon
fibroblast
mef
cell
transfect
select
activ
syk
sirna
b
c
g
h
j
order
determin
sirna
activ
antivir
cellular
pathway
mef
cell
previous
shown
express
interferonrespons
gene
respons
sirna
therefor
repres
valid
experiment
system
syk
sirna
c
h
increas
express
twofold
suggest
activ
ifn
respons
fig
gapdh
sirna
well
syk
sirna
b
g
j
without
effect
express
abil
select
activ
syk
sirna
g
j
block
fcerimedi
signal
transduct
examin
cell
crosslink
fceri
receptor
cell
led
rapid
phosphoryl
syk
tyrosin
fig
addit
syk
substrat
lat
tyrosin
tyrosin
well
associ
protein
tyrosin
downstream
protein
erk
threonin
also
phosphoryl
gener
activ
protein
tyrosin
phosphoryl
predomin
signal
kda
also
observ
respons
fceri
receptor
crosslink
consist
result
present
fig
syk
sirna
potent
reduc
level
syk
protein
sequenc
j
h
respect
less
potent
sequenc
phosphoryl
lat
erk
decreas
syk
sirna
manner
directli
correl
effect
syk
express
interestingli
whilst
tyrosin
phosphoryl
protein
kda
reduc
syk
sirna
phosphoryl
kda
protein
slightli
enhanc
suggest
phosphoryl
unidentifi
kda
protein
could
neg
regul
syk
respons
fceri
receptor
crosslink
total
level
lat
erk
bactin
affect
syk
sirna
indic
observ
reduct
respect
phosphoform
due
decreas
phosphoryl
decreas
stabil
express
use
smallmolecul
inhibitor
syk
kinas
domain
piceatannol
investig
similar
inhibit
fceri
signal
could
observ
syk
inhibitor
syk
sirna
fceriinduc
phosphoryl
lat
erk
protein
kda
dosedepend
inhibit
compound
fig
interestingli
contrast
effect
syk
sirna
phosphoryl
kda
protein
decreas
may
repres
discrep
mechan
action
two
inhibitori
approach
phosphoryl
syk
tyrosin
unaffect
inhibitor
suggest
although
activ
follow
fceri
crosslink
substrat
syk
autocatalyt
activ
use
lm
piceatannol
led
minor
decreas
phosphoryl
lat
erk
kda
protein
yet
inhibitor
without
effect
lower
concentr
lm
activ
mast
cell
basophil
via
ige
complex
lead
degranul
secret
cytokin
test
abil
syk
sirna
g
j
syk
inhibitor
block
cellular
respons
cell
three
syk
sirna
potent
block
releas
bhexosaminidas
activ
cell
fig
sequenc
g
shown
knockdown
syk
protein
lesser
extent
sirna
j
consist
releas
bhexosaminidas
inhibit
lesser
extent
syk
inhibitor
also
block
bhexosaminidas
releas
fig
interestingli
although
lm
piceatannol
shown
impact
fceri
signal
transduct
concentr
effect
block
bhexosaminidas
releas
indic
although
piceatannol
impact
sykmedi
signal
transduct
exert
unrel
antiinflammatori
effect
activ
cell
syk
sirna
inhibitor
also
block
releas
tnfa
histamin
cell
activ
via
fcericrosslink
tabl
syk
wide
express
immun
system
implic
transmiss
signal
via
fc
receptor
cell
surfac
protein
led
syk
gain
great
deal
interest
potenti
therapeut
target
treatment
inflammatori
diseas
asthma
rheumatoid
arthriti
ra
lupu
meanwhil
recent
report
sug
gest
syk
may
repres
novel
therapeut
target
treatment
b
cell
lymphoma
current
approach
toward
syk
inhibit
includ
use
small
molecul
kinas
domain
inhibitor
particular
compound
shown
efficaci
anim
human
model
ra
immun
thrombocytopen
purpura
itp
novel
approach
toward
syk
inhibit
could
realiz
blockag
syk
express
use
techniqu
antisens
oligonucleotid
rnai
approach
potenti
enabl
reduct
gene
express
mean
target
modul
altern
action
smallmolecul
inhibitor
limit
number
druggabl
target
aerol
syk
antisens
oligonucleotid
show
reduc
syk
express
alveolar
macrophag
also
block
iggantigencomplex
induc
nitric
oxid
tnfa
releas
pulmonari
infiltr
inflammatori
cell
allerg
contract
trachea
studi
highlight
potenti
efficaci
target
syk
express
level
novel
therapeut
principl
airway
inflammatori
diseas
yet
potenc
differ
sirnaa
toward
syk
knockdown
also
specif
sequenc
directli
investig
studi
design
rang
differ
syk
sirna
sequenc
test
abil
knockdown
syk
rat
basophil
cell
line
syk
sirna
ac
ej
knock
syk
mrna
protein
express
test
sirna
also
abl
block
fceriinduc
signal
transduct
degranul
tnfa
releas
manner
similar
syk
inhibitor
interestingli
commonli
use
publish
syk
inhibitor
piceatannol
shown
block
cell
degranul
tnfa
releas
concentr
affect
sykmedi
signal
transduct
highlight
sykindepend
antiinflammatori
properti
compound
must
consid
futur
studi
blockag
fceri
signal
sirna
directli
proport
effect
syk
express
result
suggest
fundament
role
syk
fceri
signal
also
demonstr
efficaci
sirna
approach
target
fceridepend
allerg
respons
clinic
potenti
sirna
somewhat
limit
complic
associ
activ
cellular
antivir
interferoninduc
gene
unanticip
offtarget
effect
mrna
syk
sirna
uniqu
sequenc
display
potent
knockdown
syk
express
reduct
fceriactiv
signal
cellular
respons
coupl
lack
effect
cellular
ifn
respons
furthermor
affymetr
analysi
effect
syk
sirna
global
express
rat
mrna
cell
reveal
offtarget
regulatori
effect
data
shown
identif
sequenc
desir
vitro
profil
rais
possibl
sequenc
becom
candid
progress
sykdepend
diseas
model
vivo
limit
factor
potenti
sirna
therapeut
includ
complic
regard
effici
deliveri
specif
target
cell
mainten
sirna
vivo
stabil
airway
deliveri
sirna
via
inhal
advantag
potenti
limit
system
distribut
molecul
whilst
local
target
airway
cell
gene
airway
sirna
alreadi
demonstr
effici
local
knockdown
target
includ
heme
dehydrogenas
gapdh
well
blockag
replic
pathogen
influenza
viru
respiratori
syncyti
viru
rsv
sar
coronaviru
scv
futur
studi
warrant
clarifi
potenti
inhal
syk
sirna
model
airway
inflammatori
cell
vivo
would
like
thank
follow
peopl
boehring
ingelheim
pharma
excel
technic
assist
support
work
andrea
grieser
bernd
guilliard
susann
christin
pischzan
margit
rie
christin
strasser
eva
wex
would
also
like
thank
follow
academ
staff
member
boehring
ingelheim
pharma
support
contribut
dr
thierri
bouyssou
florian
gantner
matthia
cell
treat
syk
sirna
kinas
inhibitor
b
activ
overnight
incub
mous
antidnp
ige
antibodi
follow
addit
dnpbsa
bhexosaminidas
activ
measur
cultur
supernat
describ
section
error
bar
repres
standard
deviat
mean
quadrupl
determin
pair
student
ttest
use
compar
statist
signific
differ
data
point
treatment
syk
sirna
inhibitor
led
significantli
reduc
secret
bhexosaminidas
compar
control
pvalu
less
syk
knockdown
kinas
inhibitor
block
tnfa
express
degranul
histamin
cell
treat
smallmolecul
inhibitor
sirna
prior
activ
fceri
receptor
ige
dnpalbumin
describ
section
percentag
releas
tnfa
histamin
compar
igednp
alon
present
grauert
tobia
hildebrandt
silk
hobbi
matthia
hoffmann
takeshi
kono
peter
seither
eric
simon
stefanlutz
wollin
